5-HETrE

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 5-HETrE
• 英文别名: (6E,8Z,11Z)-5-hydroxyicosa-6,8,11-trienoic acid
• 化学式: C₂₀H₃₄O₃
• 分子量: 322.5
• InChiKey: LSADDRSUZRRBAN-SRMUOKRHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  23
• 可旋转键数：
  15
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS
  申请人：Powell William S.

  公开号：US20120122942A1

  公开（公告）日：2012-05-17

  The present invention relates to novel pharmaceutically-useful compounds which are antagonists of the 5-oxo-ETE receptors, such as the OXE receptor. These compounds have use as therapeutic and/or prophylactic agents for diseases characterized by tissue eosinophilia, such as inflammatory conditions including respiratory diseases. The invention also relates to pharmaceutical compositions, to the use of such compounds and compositions as medicaments, and to therapeutic methods.

  本发明涉及一种新型药用化合物，其为5-oxo-ETE受体（如OXE受体）的拮抗剂。这些化合物可用作治疗和/或预防组织嗜酸性细胞增多症的疾病的治疗剂和/或预防剂，例如包括呼吸系统疾病在内的炎症性疾病。本发明还涉及制药组合物，使用这种化合物和组合物作为药物以及治疗方法。
• Topical compositions comprising polyunsaturated fatty acids
  申请人：DS Biopharma Limited

  公开号：US10328046B2

  公开（公告）日：2019-06-25

  The present invention provides a compound which is a polyunsaturated fatty acid (PUFA) derivative of formula (I), or a pharmaceutically acceptable salt, or solvate thereof, for use in treating various skin disorders.

  本发明提供了一种化合物，它是式 (I) 的多不饱和脂肪酸 (PUFA) 衍生物、 或其药学上可接受的盐或溶液，用于治疗各种皮肤疾病。
• USE OF PUFAS FOR TREATING SKIN INFLAMMATION
  申请人：DS Biopharma Limited

  公开号：EP2424520B1

  公开（公告）日：2019-07-24
• INDOLE ANALOGS AS 5-OXO-ETE RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF
  申请人：The Royal Institution for the Advancement of Learning / McGill University

  公开号：EP3277665B1

  公开（公告）日：2020-03-04
• USE OF PUFAS TO TREAT NERVE DAMAGE
  申请人：Kelliher Adam

  公开号：US20120122982A1

  公开（公告）日：2012-05-17

  The present invention provides use of compounds which are polyunsaturated fatty acid (PUFA) derivatives of formula (I), in the form of racemates, stereoisomers or mixtures of stereoisomers, or pharmaceutically acceptable salts, or solvates thereof, wherein -AIk- is —(CH 2 ) 4 —CH(OR 2 )-[trans]CH═CH-[cis]CH═CH—, —(CH 2 ) 4 -[cis]CH═CH-[trans]CH═CH—CH(OR 2 )—, —CH(OR 2 )-[trans]CH═CH-[cis]CH═CH—CH 2 -[cis]CH═CH—(CH 2 ) 3 —, —(CH 2 ) 3 —CH(OR 2 )-[trans]CH═CH-[cis]CH═CH—CH 2 -[cis]CH═CH—, or —(CH 2 ) 3 -[cis]CH═CH—CH 2 -[cis]CH═CH-[trans]CH═CH—CH(OR 2 )—; R 1 is a hydrogen atom; or R 1 is a C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 6 -C 10 aryl, 5- to 10-membered heteroaryl, C 3 -C 7 carbocyclyl or 5- to 10-membered heterocyclyl group; or R 1 is a group of formula —CH 2 —CH(OR 3 )—CH 2 —(OR 4 ), wherein R 3 and R 4 are each independently hydrogen atoms or —(C═O)—R 6 , wherein R 6 is an aliphatic group having from 3 to 29 carbon atoms; or R 1 is a group of formula —(CH 2 OCH 2 ) m OH, wherein m is an integer of from 1 to 200; or R 1 is a drug moiety; each R 2 is the-same or different- and each independently represents a hydrogen atom; or a group —(C═O)—R 5 , wherein R 5 is a C 1 -C 6 alkyl, C 2 -C6 alkenyl, C 2 -C 6 alkynyl, C 6 -C 10 aryl, 5- to 10-membered heteroaryl, C 3 -C 7 carbocyclyl or 5- to 10-membered heterocyclyl group, or R 5 is an aliphatic group having from 3 to 29 carbon atoms, or R 5 is a drug moiety; or a group of formula —(CH 2 OCH 2 ) n OH, wherein n is an integer of from 1 to 200; or a drug moiety; and wherein said alkyl, alkenyl, alkynyl and aliphatic groups are the same or different and are each unsubstituted or substituted with 1, 2 or 3 unsubstituted substituents which are the same or different and are selected from halogen atoms and C 1 -C 4 alkoxy, C 2 -C 4 alkenyloxy, C 1 -C 4 haloalkyl, C 2 -C 4 haloalkenyl, C 1 -C 4 haloalkoxy, C 2 -C 4 haloalkenyloxy, hydroxyl, —SR′, and —NR′R″ groups where R′ and R″ are the same or different and represent hydrogen or unsubstituted C 1 -C 2 alkyl; said aryl, heteroaryl, carbocyclyl and heterocyclyl groups are the same or different and are each unsubstituted or substituted by 1, 2, 3 or 4 unsubstituted substituents which are the same or different and are selected from halogen atoms, and cyano, nitro, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 2 -C 4 alkenyl, C 2 -C 4 alkenyloxy, C 1 -C 4 haloalkyl, C 2 -C 4 haloalkenyl, C 1 -C 4 haloalkoxy, C 2 -C 4 haloalkenyloxy, hydroxyl, C 1 -C 4 hydroxyalkyl, —SR′ and —NR′R″ groups wherein each R′ and R″ is the same or different and represents hydrogen or unsubstituted C 1 -C 4 alkyl; in the manufacture of a medicament for use in treating or preventing nerve damage in a mammal.